Latest:
Dr Hwang on the Potential Use of Multicancer Early Detection Tests in Breast Cancer Screening
Shelley Hwang, MD, MPH, discusses the potential use of multicancer early detection tests in breast cancer screening.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Amit Patel, BSc, MBBS, PhD, The Christie NHS Foundation Trust
Latest:
Research on CAR T Therapy in Earlier Lines of Treatment
Amit Patel, BSc, MBBS, PhD, discusses currently ongoing clinical trials of CAR T-cell therapy in first- and second-line treatment settings and comments on potential developments on the horizon.
Karolina Faysman, RN, MSN, AOCNP, DNPc
Latest:
Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)
Karolina Faysman, RN, MSN, AOCNP, DNPc, highlights efficacy, safety, and patient-reported outcomes from the phase 2 AGAVE-201 trial evaluating axatilimab for chronic graft-versus-host disease.
Ulka N. Vaishampayan, MBBS, FAB
Latest:
Dr Vaishampayan on Patient Considerations When Choosing Between FDA-Approved Therapies in nmCRPC
Ulka Nitin Vaishampayan, MBBS, discusses patient factors to consider when choosing between apalutamide, enzalutamide, and darolutamide for the treatment of patients with non-metastatic castration resistant prostate cancer.
Hannah Choe, MD
Latest:
Clinical Scenario and Perspectives on the Evolving Treatment Landscape in GVHD
Dr. Hannah Choe discusses a clinical scenario of a patient with GVHD who has progressed after multiple lines of treatment. She explores how the availability of CSF-1R inhibitors could fit into the evolving treatment landscape for managing this difficult-to-treat patient population. Dr. Choe provides her perspectives on the potential role and clinical implications of targeting this pathway as an emerging therapeutic approach for GVHD.
Cesar Gentille Sanchez, MD
Latest:
Leveraging BTK Inhibitors in Chronic Lymphocytic Leukemia
The choice of BTK inhibitor regimen for patients with chronic lymphocytic leukemia must be tailored to the patient, taking into consideration their preferences and comorbidities, as well as potential treatment-related adverse effects.